See more : Pak Fah Yeow International Limited (0239.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Skye Bioscience, Inc. (SKYE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Skye Bioscience, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Kenedix Office Investment Corporation (8972.T) Income Statement Analysis – Financial Results
- Spacefy Inc. (SPFY.CN) Income Statement Analysis – Financial Results
- Fuso Chemical Co.,Ltd. (4368.T) Income Statement Analysis – Financial Results
- Accretion Acquisition Corp. (ENERR) Income Statement Analysis – Financial Results
- Unifin Financiera, S. A. B. de C. V. (UNIFINA.MX) Income Statement Analysis – Financial Results
Skye Bioscience, Inc. (SKYE)
About Skye Bioscience, Inc.
Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 339.93K | 16.24K |
| Cost of Revenue | 124.25K | 115.00K | 34.13K | 1.87K | 1.46K | 1.54K | 8.04K | 14.92K | 9.95K | 0.00 | 131.34K | 5.36K |
| Gross Profit | -124.25K | -115.00K | -34.13K | -1.87K | -1.46K | -1.54K | -8.04K | -14.92K | -9.95K | 0.00 | 208.59K | 10.89K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 61.36% | 67.03% |
| Research & Development | 5.82M | 6.01M | 2.93M | 1.94M | 2.24M | 329.97K | 311.30K | 939.04K | 576.09K | 227.50K | 0.00 | 0.00 |
| General & Administrative | 7.85M | 6.09M | 4.92M | 4.34M | 4.39M | 4.36M | 3.55M | 3.53M | 3.74M | 2.50M | 120.40K | 6.37K |
| Selling & Marketing | -124.25K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.73M | 6.09M | 4.92M | 4.34M | 4.39M | 4.36M | 3.55M | 3.53M | 3.74M | 2.50M | 120.40K | 6.37K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 102.85K | -48.56K | -1.00M | 0.00 | 67.30K | 396.00 |
| Operating Expenses | 13.55M | 12.11M | 7.85M | 6.29M | 6.63M | 4.69M | 3.86M | 4.47M | 4.32M | 2.73M | 120.40K | 6.77K |
| Cost & Expenses | 13.67M | 12.11M | 7.85M | 6.29M | 6.63M | 4.69M | 3.86M | 4.47M | 4.32M | 2.73M | 120.40K | 12.13K |
| Interest Income | 99.97K | 19.01K | 3.00 | 29.00 | 26.00 | 84.00 | 0.00 | 0.00 | 0.00 | 0.00 | 789.00 | 638.00 |
| Interest Expense | 906.27K | 665.13K | 767.51K | 706.39K | 987.80K | 94.76K | 667.00 | 0.00 | 522.34K | 0.00 | 2.15K | 638.00 |
| Depreciation & Amortization | 124.25K | 115.00K | 34.13K | 1.87K | 1.46K | 1.54K | 8.04K | 14.92K | 9.95K | 1.91K | 16.48K | 638.00 |
| EBITDA | -13.55M | -12.09M | -7.81M | -6.29M | 2.04M | -4.69M | -3.85M | 0.00 | 0.00 | 0.00 | -7.24K | 4.76K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -35.42% | 29.27% |
| Operating Income | -13.67M | -18.31M | -7.85M | -6.29M | -6.63M | -4.69M | -3.86M | -4.47M | -4.32M | -2.73M | -120.40K | 4.12K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -35.42% | 25.35% |
| Total Other Income/Expenses | -23.97M | -7.37M | -672.37K | -270.09K | 7.69M | -14.50M | 766.53K | 1.29M | -522.34K | 0.00 | 3.46K | 638.00 |
| Income Before Tax | -37.64M | -19.47M | -8.52M | -6.56M | 1.05M | -19.19M | -3.09M | -3.18M | -4.84M | -2.73M | -3.78K | 4.76K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1.11% | 29.27% |
| Income Tax Expense | 3.60K | 6.74K | 2.10K | 1.60K | 1.60K | 1.64K | 1.60K | 1.60K | 1.72K | 2.51K | -3.46K | 246.00 |
| Net Income | -37.64M | -19.48M | -8.52M | -6.56M | 1.05M | -19.19M | -3.09M | -3.18M | -4.84M | -2.73M | -120.40K | 4.51K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -35.42% | 27.76% |
| EPS | -5.37 | -9.82 | -5.24 | -6.39 | 1.98 | -36.51 | -25.62 | -41.93 | -71.45 | -65.08 | -3.52 | 0.13 |
| EPS Diluted | -5.37 | -9.82 | -5.15 | -6.39 | 1.98 | -36.51 | -25.62 | -39.90 | -70.93 | -65.08 | -3.52 | 0.13 |
| Weighted Avg Shares Out | 7.01M | 1.98M | 1.63M | 1.03M | 532.01K | 525.78K | 120.77K | 75.79K | 67.75K | 42.01K | 34.21K | 34.21K |
| Weighted Avg Shares Out (Dil) | 7.01M | 1.98M | 1.65M | 1.03M | 532.01K | 525.78K | 120.77K | 79.65K | 68.25K | 42.01K | 34.21K | 34.21K |
Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor
SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that it has achieved more than 50% of targeted patient enrollment...
Skye Bioscience, Inc. (SKYE) Q3 2024 Earnings Call Transcript
Skye Bioscience, Inc. (NASDAQ:SKYE ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Bernie Hertel - Head, Investor Relations Punit Dhillon - President and CEO Kaitlyn Arsenault - Chief Financial Officer Chris Twitty - Chief...
Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today reported financial results for the third quarter ended September 30,...
Skye Bioscience to Announce Third Quarter 2024 Results
SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that the company's third quarter 2024 financial results will be released...
Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences
SAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that it will participate in the following upcoming healthcare investment conferences:
Don't Sleep on Skye Bioscience—This Weight Loss Drug Could Soar
Skye Bioscience NASDAQ: SKYE is a micro-cap pharmaceutical company that is striving to become the next big thing in the weight loss drug space. The massive success of glucagon-like peptide-1 (GLP-1) agonist drugs sold by Eli Lilly NYSE: LLY and...
3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn't Ignore
Micro-cap stocks are typically categorized as companies with market capitalizations between $50 million and $300 million. However, it's not a hard-and-fast rule.
Skye: Moving Weight Loss Drugs To The Next Level
Skye Bioscience, Inc. interim data from phase 2 CBeyond study, using nimacimab for the treatment of patients with obesity, is expected Q2 and Q4 of 2025. Experimental arm added into phase 2 CBeyond study, which is combining the use of...
Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences
SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that it will participate in the following upcoming healthcare investment conferences:
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that on August 22, 2024, the Board of Directors granted a...
Source: https://incomestatements.info
Category: Stock Reports